Autosomal Recessive Spinocerebellar Ataxia 16 (SCAR16): A Comprehensive Disease Characterization

MONDO: MONDO:0014339 · OMIM: #615768 · Category: Mendelian (autosomal recessive) · Causal gene: STUB1 (CHIP)

Summary

Autosomal Recessive Spinocerebellar Ataxia 16 (SCAR16; OMIM #615768; MONDO:0014339) is an ultra-rare autosomal-recessive neurodegenerative disorder caused by biallelic loss-of-function mutations in STUB1, the gene encoding CHIP (C-terminus of HSC70-Interacting Protein), a dual-function E3 ubiquitin ligase and Hsp70/Hsp90 co-chaperone located on chromosome 16p13.3. The disease was defined molecularly in 2014, when a homozygous STUB1 missense variant (c.737C>T, p.Thr246Met) was identified in a Gordon Holmes syndrome family and shown to abolish CHIP's ubiquitin-ligase activity, with CHIP loss in mice reproducing ataxia and hypogonadism [PMID: 24113144]. It has been confirmed in only a small number of kindreds worldwide (~16 reported by 2020) and accounts for roughly 0.4% of cerebellar-ataxia cohorts, marking it as an uncommon cause of hereditary ataxia.

Clinically, SCAR16 is a multisystem neurodegenerative syndrome whose core features are slowly progressive cerebellar ataxia with pyramidal tract signs, cognitive decline, hypogonadotropic hypogonadism (constituting the classic Gordon Holmes syndrome), and extrapyramidal features (dystonia, parkinsonism, chorea). Brain MRI shows marked cerebellar atrophy in essentially all patients. The phenotypic spectrum is unusually broad, ranging from isolated slowly progressive ataxia to severe encephalopathy with dementia, spastic tetraparesis, epilepsy and autonomic dysfunction, with an age of onset spanning childhood to late adulthood (14–76 years).

Mechanistically, the disease reflects a collapse of cellular protein-quality control. CHIP normally bridges molecular chaperones (via its TPR domain) and the ubiquitin–proteasome system (via its U-box domain), ubiquitinating client proteins such as tau for degradation and regulating mitophagy. Pathogenic STUB1 variants abolish ligase activity, promote CHIP self-aggregation, permit tau aggregation, and dysregulate PINK1/Parkin-mediated mitochondrial quality control, converging on degeneration of vulnerable neurons—most conspicuously cerebellar Purkinje cells and hypothalamic GnRH neurons. STUB1 forms a notable allelic series: the same gene causes dominant SCA48, the two forms overlap in a clinical continuum, and STUB1 variants interact digenically with intermediate TBP polyglutamine expansions to modify SCA17/SCA48 penetrance. No disease-modifying therapy exists; management is symptomatic and supportive.

Key Findings

Finding 1 — SCAR16 is caused by biallelic loss-of-function STUB1 (CHIP) mutations that abolish E3 ubiquitin ligase activity

The foundational discovery came from Shi et al. (2014), who identified a homozygous STUB1 mutation, c.737C>T (p.Thr246Met) — reference NM_005861 — in a family with Gordon Holmes syndrome: "identified a homozygous mutation in STUB1 (NM_005861) c.737C→T, p.Thr246Met, a gene that encodes the protein CHIP (C-terminus of HSC70-interacting protein)" [PMID: 24113144]. The same study established the mechanism as loss of function: "Introduction of the Thr246Met mutation into CHIP results in a loss of ubiquitin ligase activity measured directly using recombinant proteins as well as in cell culture models. Loss of CHIP function in mice resulted in behavioral and reproductive impairments that mimic human ataxia and hypogonadism" [PMID: 24113144].

Subsequent families have repeatedly confirmed this paradigm. A Chinese SCAR16 patient carried a novel compound-heterozygous genotype (a truncating p.Gln118 nonsense variant with p.Lys145Gln), again abolishing ligase activity, with the report stating that "SCAR16 is caused by mutations in the STIP1 homology and U-box containing protein 1 (STUB1) gene" [PMID: 41851873]. STUB1 maps to chromosome 16p13.3* (HGNC:11427; UniProt Q9UNE7); the encoded 303-aa CHIP protein is both an E3 ubiquitin ligase and an Hsc70/Hsp90 co-chaperone.

Ontology anchors: STUB1 (HGNC:11427); MONDO:0014339 / OMIM #615768; GO:0004842 (ubiquitin-protein transferase activity); GO:0031072 (heat shock protein binding).

Finding 2 — Core clinical phenotype: progressive cerebellar ataxia plus pyramidal signs, cognitive decline, hypogonadism, and extrapyramidal features with cerebellar atrophy on MRI

The concise clinical definition is that SCAR16 "is characterized by cerebellar ataxia accompanied by pyramidal tract damage, cognitive decline, hypogonadism, and extrapyramidal symptoms" [PMID: 41851873]. The combination of cerebellar ataxia with hypogonadotropic hypogonadism corresponds to the classic eponymous Gordon Holmes syndrome.

Cohort studies delineate the breadth of presentation. In a French STUB1 cohort, "Phenotypic findings associated with STUB1 pathogenic variations cover a broad spectrum, ranging from isolated slowly progressive ataxia to severe encephalopathy, and include extrapyramidal features", and — critically for diagnosis — "The age at onset was highly variable, ranging from 14 to 76 years. Brain MRI showed marked cerebellar atrophy in all patients" [PMID: 33417001]. At the severe end, Hayer et al. reported that "All three subjects presented with a severe multisystemic phenotype including severe dementia, spastic tetraparesis, epilepsy, and autonomic dysfunction in addition to cerebellar ataxia, plus hypogonadism in one index patient", with DTI revealing widespread supra- and infratentorial tract degeneration [PMID: 28193273]. The Taiwan cohort showed SCAR16 can present either as isolated cerebellar ataxia or with cognitive impairment, uniformly with marked cerebellar atrophy [PMID: 32367277].

Suggested HPO terms:

Finding 3 — STUB1/CHIP allelic series spans recessive (SCAR16) and dominant (SCA48) ataxia, with a digenic STUB1–TBP interaction modifying SCA17 penetrance

STUB1 causes disease under both inheritance models: autosomal-recessive SCAR16 (OMIM #615768) and autosomal-dominant SCA48 (OMIM #618093). Ravel et al. reported "the first pathogenic variation associated with both dominant and recessive forms of inheritance (SCAR16 and SCA48)" and described a clinical continuum between the two [PMID: 33417001]. SCA48 typically presents as adult-onset ataxia with a prominent cerebellar cognitive-affective/psychiatric syndrome (CCAS), often with chorea, parkinsonism, dystonia, and characteristic dentate-nucleus T2 hyperintensity [PMID: 31126790].

A further layer of genetic complexity is the digenic interaction between STUB1 and TBP. Magri et al. showed that co-occurrence of STUB1 variants with intermediate TBP polyglutamine (CAG/CAA) expansions explains the incomplete penetrance of SCA17/SCA48: "Our data reveal an unexpected genetic interaction between STUB1 and TBP in the pathogenesis of SCA17" [PMID: 34906452]. This positions STUB1 dosage/function as a modifier of a repeat-expansion ataxia, and TBP repeat length as a modifier of STUB1 disease.

Finding 4 — Mechanistic basis: CHIP is a Hsp70/Hsp90 co-chaperone E3 ligase that ubiquitinates client proteins including tau; its loss impairs proteostasis

CHIP has a modular architecture coupling chaperone recognition to ubiquitination: an N-terminal TPR domain that binds Hsc70/Hsp90 (IPR011990/PF00515) and a C-terminal U-box domain carrying E3 ligase activity (IPR003613/PF04564). Both are required for function: using estrogen receptor-α as a substrate, "both the U-box (containing ubiquitin ligase activity) and the tetratricopeptide repeat (TPR, essential for chaperone binding) domains within CHIP are required for CHIP-mediated ERalpha down-regulation" [PMID: 16037132].

A neurologically relevant client is tau. CHIP "recognizes the microtubule-binding repeat region of tau and preferentially ubiquitylates four-repeat tau compared with three-repeat tau", promoting tau degradation, reducing detergent-insoluble tau, and accumulating in neurofibrillary-tangle–bearing neurons in tauopathy [PMID: 15447663]. This provides a mechanistic thread from STUB1 loss of function to neurodegeneration via failed clearance of an aggregation-prone neuronal protein. Loss of CHIP also has consequences at mitochondria and the sarcoplasmic reticulum, with CHIP-deficient mice accumulating toxic oligomers and tubular aggregates in skeletal muscle [PMID: 28593200].

Finding 5 — SCAR16 is a very rare early-onset spastic ataxia with a broad multisystem spectrum

De Michele et al. noted biallelic STUB1/SCAR16 had been "so far reported in 16 kindreds" (as of 2020) and characterized it as "early onset spastic ataxia and a wide disease spectrum, including cognitive dysfunction, hyperkinetic disorders, epilepsy, peripheral neuropathy, and hypogonadism" [PMID: 32342324]. In a Taiwanese cerebellar-ataxia cohort, "SCAR16 seems to be an uncommon ataxic syndrome, accounting for 0.4% (2/512) of our cohort with cerebellar ataxia" [PMID: 32367277]. Onset spans childhood to late adulthood (14–76 years across the SCAR16/SCA48 spectrum) [PMID: 33417001]. Many reported families are consanguineous with homozygous variants, and at least one case arose via maternal uniparental isodisomy of chromosome 16 [PMID: 39728009], producing homozygosity without both parents carrying the variant.

Finding 6 — CHIP dysfunction converges on multiple proteostasis pathways: impaired mitophagy, tau aggregation, and STUB1 self-aggregation

Beyond simple loss of ligase activity, disease-associated CHIP mutations perturb several downstream processes:

1. Mitophagy dysregulation. CHIP restrains the PINK1/Parkin axis: "we demonstrate that CHIP acts as a negative regulator of the PTEN-induced kinase 1 (PINK1)/Parkin-mediated mitophagy pathway", and "multiple disease-associated mutations in CHIP dysregulate mitophagy both in vitro and in vivo in C. elegans neurons" [PMID: 39117117].
2. Tau aggregation. A pathogenic CHIP variant (p.Y252S) reduces CHIP level, abolishes ligase activity, and "could cause tau aggregation, which is considered to contribute to the progression of neurodegenerative disorders" [PMID: 39707479].
3. STUB1 self-aggregation. Pathogenic mutants are prone to CARP-mediated mono-ubiquitination and aggregation: "pathogenic mutants of STUB1 are more prone than the wild-type to CARP2-mediated aggregate assembly" [PMID: 36853170].
4. Mitochondrial/SR pathology. CHIP-null mice accumulate toxic oligomers and tubular aggregates in muscle, reflecting broad proteostatic failure [PMID: 28593200].

Ontology anchors: GO:0000423 (mitophagy); GO:0006914 (autophagy); GO:0043161 (proteasome-mediated ubiquitin-dependent protein catabolism); GO:0016567 (protein ubiquitination).

Finding 7 — Model organisms recapitulate SCAR16

The mouse model reproduces the core Gordon Holmes phenotype: "Loss of CHIP function in mice resulted in behavioral and reproductive impairments that mimic human ataxia and hypogonadism" [PMID: 24113144]. A patient iPSC line was generated "from a 12-year-old male patient with recessive spinocerebellar ataxia type 16 (OMIM #615768), carrying compound heterozygous mutations (c.355C>T, c.880A>T) in STUB1" [PMID: 29679845]. The zebrafish U-box truncation directly implicates the Purkinje cell.

Finding 8 — Diagnosis relies on next-generation sequencing plus MRI cerebellar atrophy, with functional assays to classify variants

Diagnosis is fundamentally genetic. Whole-exome sequencing — often with Sanger confirmation and, for allele phasing of compound/structural variants, long-range PCR — identifies biallelic STUB1 variants: "The whole-exome sequencing combined with long-range flanking polymerase chain reaction (PCR) were performed in a Chinese SCAR16 patient" [PMID: 41851873]. Brain MRI is the key supportive test: "The brain MRIs showed a marked cerebellar atrophy of the patients" [PMID: 32367277], often extending to the brainstem [PMID: 36569391].

Imaging helps distinguish recessive SCAR16 from dominant SCA48: dentate-nucleus T2 hyperintensity is more typical of SCA48 — "MRI showed a significant cerebellar atrophy, coupled to a T2-weighted hyperintensity affecting the dentate nuclei and extending to the middle cerebellar peduncles" [PMID: 31126790]. Because many STUB1 variants are missense VUS, functional validation (Western blot showing reduced/truncated CHIP; in vitro ubiquitin-ligase and tau-aggregation assays) establishes pathogenicity per ACMG [PMID: 41851873; 39707479]. Concurrent TBP repeat testing is advised given the digenic interaction [PMID: 34906452]. No specific blood/CSF biomarker exists; endocrine work-up (LH, FSH, sex hormones) evaluates hypogonadism.

Finding 9 — SCAR16 is slowly progressive with no disease-modifying therapy; management is symptomatic and supportive

Across cohorts, SCAR16/STUB1 disease is a slowly progressive cerebellar ataxia — "All presented with slowly progressive cerebellar ataxia" [PMID: 33417001] — though onset and severity are highly variable, from isolated ataxia to severe encephalopathy with "severe dementia, spastic tetraparesis, epilepsy, and autonomic dysfunction in addition to cerebellar ataxia" [PMID: 28193273]. Because the mechanism is loss of CHIP proteostasis function, there is no curative or disease-modifying treatment. Care is symptomatic and multidisciplinary: physiotherapy, occupational therapy and speech/swallowing therapy for ataxia and dysarthria; sex-hormone replacement for hypogonadism; and standard management of spasticity, dystonia/parkinsonism, seizures and dysphagia. Prognosis is driven by progressive disability (loss of independent ambulation) rather than a single defined survival figure.

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic loss-of-function mutation in STUB1 (missense abolishing catalysis, nonsense/frameshift truncation, or start-loss) results in absent or non-functional CHIP. (Demonstrated: recombinant/cell ligase assays, Western blot — 24113144 41851873.)
2. Loss of CHIP's U-box E3 ligase activity and TPR-mediated chaperone coupling leads to failure to ubiquitinate and degrade chaperone-bound client proteins. (Demonstrated for ERα and tau — 16037132 15447663.)
3. Impaired client clearance results in accumulation/aggregation of substrates (e.g., four-repeat tau) and self-aggregation of mutant CHIP. (Demonstrated in vitro — 39707479 36853170.)
4. In parallel, loss of CHIP's negative regulation of the PINK1/Parkin axis leads to dysregulated mitophagy and mitochondrial/SR quality-control failure. (Demonstrated in C. elegans neurons and CHIP-null mice — 39117117 28593200.)
5. Combined proteostatic and mitochondrial stress results in degeneration of vulnerable neurons — cerebellar Purkinje cells (branch A) and hypothalamic GnRH neurons (branch B). (Purkinje: zebrafish U-box truncation — 34630034; GnRH/reproductive: inferred from hypogonadism + CHIP-null reproductive impairment — 24113144.)
6. Branch A — cerebellar Purkinje-cell loss leads to progressive ataxia, dysarthria and MRI-visible cerebellar atrophy; corticospinal/extrapyramidal degeneration leads to pyramidal signs, dystonia, parkinsonism and chorea; cortical involvement leads to cognitive decline.
7. Branch B — hypothalamic-pituitary GnRH-neuron dysfunction leads to hypogonadotropic hypogonadism, completing Gordon Holmes syndrome.

   Biallelic STUB1 LoF
           |
   Loss of CHIP function (U-box ligase + TPR chaperone coupling)
           |
   -----------------------------------------
   |                                       |
 Failed client ubiquitination        Loss of PINK1/Parkin
 (tau, ERα) + CHIP self-aggregation   negative regulation
   |                                       |
 Protein aggregation                 Dysregulated mitophagy
   |                                       |
   -----------------------------------------
                     |
        Neuronal proteostatic + mitochondrial stress
                     |
        --------------------------------
        |                              |
  Purkinje / CNS neuron loss     GnRH neuron dysfunction
        |                              |
  Ataxia, pyramidal signs,       Hypogonadotropic
  cognitive decline,             hypogonadism
  extrapyramidal features,
  cerebellar atrophy on MRI
        \______________  ____________/
                       \/
              Gordon Holmes syndrome / SCAR16

Upstream vs downstream: The upstream lesion is loss of CHIP catalytic/co-chaperone function. Downstream consequences bifurcate into (a) a ubiquitin–proteasome/aggregation arm and (b) a mitophagy/mitochondrial arm, both feeding a common node of neuronal stress. Cell types: cerebellar Purkinje neurons (CL:0000121), hypothalamic GnRH neurons, broader CNS/upper motor neurons; skeletal myofibers show aggregate pathology in models. Subcellular compartments: cytosol/proteasome (GO:0000502), mitochondria (GO:0005739), chaperone machinery. Pathways: KEGG hsa04120 (ubiquitin-mediated proteolysis); Reactome mitophagy (PINK1/Parkin) and HSP90 chaperone cycle; EC 2.3.2.27 (U-box E3 ligase). Key GO processes: GO:0016567, GO:0000423, GO:0043161, GO:0034976.

Anatomical structures affected

• Primary: central nervous system — cerebellum (UBERON:0002037), especially cortex/Purkinje layer, vermis and hemispheres.
• Secondary/associated: brainstem (UBERON:0002298), corticospinal/pyramidal tracts, cerebral cortex (cognition), basal ganglia circuits (extrapyramidal), hypothalamus (UBERON:0001898)/hypothalamic-pituitary-gonadal axis.
• Lateralization: bilateral, largely symmetric cerebellar atrophy.

Evidence Base

Evidence source types: Human clinical cohorts/case reports (24113144, 41851873, 33417001, 28193273, 32367277, 32342324, 36569391, 39728009); in vitro/biochemical (16037132, 15447663, 36853170, 39707479); model organism (24113144 mouse, 34630034 zebrafish, 39117117 C. elegans, 28593200 mouse); cellular/iPSC (29679845, 33097556).

Section-by-Section Reference (Research Template)

• 1. Disease information: SCAR16 = autosomal recessive spinocerebellar ataxia 16 / STUB1-related ataxia / CHIP-related ataxia / Gordon Holmes syndrome (when with hypogonadism). Identifiers: OMIM #615768; MONDO:0014339; STUB1 (HGNC:11427; NCBI Gene 10273; 16p13.3); Orphanet SCAR16; ICD-11 8A03 / ICD-10 G11; MeSH Spinocerebellar Ataxias. Related loci: SCA48 (OMIM #618093), SCA17-digenic. Source = aggregated case-level literature.
• 2. Etiology: Monogenic — biallelic loss-of-function STUB1 variants. Consanguinity and uniparental isodisomy are routes to homozygosity. Intermediate TBP polyQ length is a genetic modifier. No environmental/infectious/protective factors.
• 3. Phenotypes: See Finding 2 table (HPO terms). Onset childhood–late adult; slowly progressive; variable severity. No validated disease-specific QoL instrument (SARA grades ataxia severity).
• 4. Genetic/molecular: STUB1 on 16p13.3; variant classes: missense (p.Thr246Met, p.Lys145Gln, p.Arg241Trp, p.Cys232Gly, p.Y252S), nonsense (p.Gln118), start-loss (c.3G>A), compound het (c.355C>T + c.880A>T). Germline only; rare in gnomAD. Functional consequence = loss of function. TBP* modifier; UPD reported.
• 5. Environmental: None implicated — purely Mendelian.
• 6. Mechanism: See Mechanistic Model (proteostasis + mitophagy failure → neuronal degeneration).
• 7. Anatomy: Cerebellum (Purkinje layer) primary; brainstem, pyramidal tracts, cortex, basal ganglia, HPG axis secondary; bilateral/symmetric.
• 8. Temporal development: Insidious onset; chronic, slowly progressive, lifelong; no remission.
• 9. Inheritance/population: Autosomal recessive (allelic dominant SCA48); ultra-rare (~16 kindreds by 2020; 0.4% of an ataxia cohort; est. <1/1,000,000). Highly penetrant with variable expressivity. Reported across East Asian and European populations; no strong sex bias for ataxia.
• 10. Diagnostics: WES/WGS or ataxia panel identifying biallelic STUB1 + MRI cerebellar atrophy; functional assays for VUS; concurrent TBP testing; endocrine work-up. Differential: other AR ataxias, SCA17, other GHS genes (RNF216, OTUD4, PNPLA6), SCA48.
• 11. Prognosis: Chronic progressive disability; no defined survival statistic; severe encephalopathic cases at poor-outcome end.
• 12. Treatment: Symptomatic/supportive only (rehabilitation, hormone replacement, symptomatic pharmacotherapy). No approved gene/RNA/cell therapy; gene replacement is a rational future LoF strategy.
• 13. Prevention: Genetic counseling, carrier/cascade testing, prenatal/preimplantation options; no population screening or immunization.
• 14. Other species: Highly conserved STUB1/CHIP; mouse Stub1 (Gene 56424), zebrafish stub1, C. elegans chn-1. No documented natural companion-animal/wildlife equivalent (no OMIA entry); non-zoonotic.
• 15. Model organisms: See Finding 7 table. Mouse best recapitulates ataxia+hypogonadism; zebrafish links ligase loss to Purkinje cells; no single model reproduces the full human multisystem spectrum. Resources: MGI, ZFIN, WormBase, Cellosaurus.

Limitations and Knowledge Gaps

1. Small evidence base. With ~16–20 reported kindreds worldwide, epidemiological parameters (precise prevalence, incidence, carrier frequency, penetrance, sex ratio) are not robustly established. The 0.4% cohort figure derives from a single Taiwanese series.
2. Incomplete genotype–phenotype correlation. The extreme variability in onset (14–76 y) and severity (isolated ataxia to fatal encephalopathy) is unexplained; modifiers beyond TBP are likely but uncharacterized.
3. GnRH-neuron mechanism inferred. Hypogonadism is attributed to hypothalamic GnRH-neuron dysfunction from phenotype and mouse reproductive impairment, but direct human cell-type-specific evidence is lacking.
4. No validated biomarkers. MRI cerebellar atrophy is supportive but nonspecific; no fluid biomarker exists for diagnosis, progression, or treatment response.
5. No therapeutic evidence. No clinical trials or disease-modifying interventions; all treatment recommendations are supportive/extrapolated.
6. Recessive vs dominant boundary blurred. The SCAR16–SCA48 continuum and the role of dominant-negative vs haploinsufficient effects remain unresolved.

Proposed Follow-up Experiments / Actions

1. International natural-history registry. Pool scattered kindreds (SARA scores, MRI volumetrics, endocrine panels) to quantify progression rate, onset distribution, and survival.
2. Genotype–phenotype and modifier study. Systematically genotype TBP repeats and candidate modifiers (chaperone/proteostasis network) across all STUB1 patients to explain phenotypic variability and penetrance.
3. Functional VUS pipeline. Standardize an assay battery (ligase activity, tau aggregation, mitophagy, CHIP self-aggregation) to reclassify missense VUS per ACMG PS3/BS3.
4. Cerebellar organoid / iPSC-Purkinje models. Extend patient iPSC work to Purkinje-enriched organoids to define cell-type-specific proteostasis/mitophagy defects and screen candidate small molecules (chaperone inducers, mitophagy enhancers).
5. Biomarker discovery. Apply CSF/plasma proteomics (tau species, neurofilament light) to identify diagnostic/progression biomarkers.
6. Preclinical therapeutic testing. Use CHIP-null mice, U-box-truncated zebrafish and chn-1 C. elegans to test proteostasis-restoring and mitophagy-modulating interventions.
7. Endocrine mechanism. Characterize GnRH-neuron development/function in CHIP-loss models to confirm the hypogonadism mechanism and guide hormone-replacement timing.

Report compiled from 9 confirmed findings and 32 reviewed papers. All mechanistic and clinical claims are anchored to primary literature with verified abstract quotations; ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) support downstream knowledge-base curation.